– Compelling early clinical response signals for VIR-5818 and VIR-5500 in heavily pretreated patients with various solid tumors VIR-5818: In patients receiving doses ≥400 µg/kg, tumor shrinkage ...
ALTON, Va., Oct. 31, 2025 /PRNewswire/ -- Crown Racing will support four drivers in the PRO 1340 class at the Radical World Finals this week at Virginia International Raceway, supporting the inaugural ...
Vir Biotechnology (VIR) is presenting initial Phase 1 data from two of its dual-masked T-cell engagers: VIR-5818, targeting a variety of HER2-expressing solid tumors; and VIR-5500, targeting PSMA in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results